Brookfield Reinsurance (NYSE:BNRE) Shares Down 1.3% - What's Next?

Key Points

• Brookfield Reinsurance (NYSE:BNRE) shares fell 1.3% mid-day to $44.94 (low $44.8120) as volume surged ~183% to about 18,065 shares versus the 6,394 average.
• Key metrics: market capitalization $6.54 billion, PE ratio 154.97, beta 1.53, with a 50‑day MA of $43.58 and 200‑day MA of $45.25.
• Bermuda‑domiciled reinsurer sponsored by Brookfield Asset Management, offering property catastrophe, casualty, specialty lines and retrocession while combining underwriting with capital‑markets strategies.

Brookfield Reinsurance Ltd. (NYSE:BNRE - Get Free Report)'s share price was down 1.3% during mid-day trading on Wednesday . The stock traded as low as $44.8120 and last traded at $44.94. Approximately 18,065 shares were traded during mid-day trading, an increase of 183% from the average daily volume of 6,394 shares. The stock had previously closed at $45.51.

Brookfield Reinsurance Stock Performance

The business's 50-day moving average is $43.58 and its 200-day moving average is $45.25. The company has a market capitalization of $6.54 billion, a PE ratio of 154.97 and a beta of 1.53.

Brookfield Reinsurance Company Profile

Brookfield Reinsurance NYSE: BNRE is a Bermuda-domiciled reinsurer sponsored by Brookfield Asset Management. The company provides a range of risk transfer solutions, including property catastrophe, casualty, specialty lines and retrocession coverage. By combining underwriting expertise with diversified capital markets strategies, Brookfield Reinsurance aims to meet the needs of primary insurers, reinsurers and other institutional clients seeking tailored reinsurance capacity.

In its underwriting operations, Brookfield Reinsurance focuses on structuring programs across regions and perils, deploying both traditional reinsurance treaties and facultative placements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.